Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
180.46
-5.70 (-3.06%)
Jul 20, 2026, 4:00 PM EDT - Market closed

Revolution Medicines Stock Forecast

Stock Price Forecast

According to 23 analysts polled by S&P Global, Revolution Medicines stock has a consensus rating of "Strong Buy" and an average price target of $200.5. The average 1-year stock price forecast is 11.10% higher than the current stock price, while the lowest is $151 (-16.32%) and the highest is $263 (+45.74%).

Price Target: $200.5 (+11.10%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$151$200.5$204.48$263
Change-16.32%+11.10%+13.31%+45.74%

Analyst Ratings

The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy171717171718
Buy444444
Hold000111
Sell000000
Strong Sell000000
Total212121222223

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
LifeSci Capital
LifeSci Capital
Buy
Maintains
$263
BuyMaintains$263+45.74%Jul 11, 2026
Truist Financial
Truist Financial
Buy
Reiterates
n/a
BuyReiteratesn/an/aJul 10, 2026
Guggenheim
Guggenheim
Buy
Maintains
$205$235
BuyMaintains$205$235+30.22%Jul 9, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$195
BuyReiterates$195+8.06%Jul 6, 2026
UBS
UBS
Buy
Reiterates
$175$220
BuyReiterates$175$220+21.91%Jul 6, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
103.14M
Revenue Next Year
863.13M
from 103.14M
Increased by 736.85%
EPS This Year
-8.03
from -5.95
EPS Next Year
-5.73
from -8.03
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
29.39M35.38M11.58M--103.14M
Gross Profit
-157.56M-217.69M-407.86M-592.23M-987.33M92.31M
Gross Margin
-536.09%-615.30%-3,522.14%--89.50%
Operating Income
-188.01M-258.28M-475.99M-689.52M-1.18B-1.70B
Net Income
-187.09M-248.71M-436.37M-600.09M-1.13B-1.65B
EPS
-----5.95-8.03
Free Cash Flow
-84.69M-132.84M-163.95M-347.69M-523.28M-1.48B
No. Analysts
-----21
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High295.1M
Avg103.1M
Lown/a

Revenue Growth

Revenue Growth20272028
High
2,241.1%
Avg
736.8%
Low
120.2%

EPS Forecast

EPS202620272028
High-7.20
Avg-8.03
Low-8.94

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-